Abstract: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-? expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-? blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-? blocking agent and treated cells are co-administered to a subject in need thereof.

Abstract: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-? expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-? blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-? blocking agent and treated cells are co-administered to a subject in need thereof.

Abstract: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-? expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-? blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-? blocking agent and treated cells are co-administered to a subject in need thereof.

Abstract: A composition antisense oligomer directed to an mRNA preferentially expressed together with methods for treating stem cells with such a composition to increase the number of lineage committed progenitor cells and their progeny, and/or slow the growth of cancer cells. Also described is the use of such compositions and antisense oligonucleotide-treated stem cells in methods for treatment of cancer.

Abstract: The invention relates to TGF-? blocking agent-treated HSC compositions and methods comprising the same. The TGF-? blocking agent-treated stem cells are viable for an extended time in culture without replication or differentiation and upon transfer to appropriate conditions are capable of long term hematopoietic reconstitution.

Abstract: The invention relates to stem cell compositions comprising anti-TGF-&bgr; treated stem cells which are viable for at least 14 days in culture without replication or differentiation and methods for rapid and long term in vitro hematopoiesis and in vivo hematopoietic reconstitution using such anti-TGF-&bgr; treated stem cells.

Abstract: The invention features a method for the expansion of hematopoietic stem cells using a combination of a thrombopoietin agonist and a transforming growth factor-beta blocking agent in the absence of stem cell factor. The invention also features a hematopoictic stem cell composition that has been expanded using a combination of a thrombopoietin agonist and a transforming growth factor-beta blocking agent in the absence of stem cell factor, as well as methods of using an expanded hematopoietic stem cell composition to restore or supplement an immune system and/or blood forming system compromised by, for example, radiation or chemotherapy.

Abstract: The invention relates to stem cell compositions comprising anti-TGF-&bgr; treated stem cells which are viable for at least 14 days in culture without replication or differentiation and methods for rapid and long term in vitro hematopoiesis and in vivo hematopoietic reconstitution using such anti-TGF-&bgr; treated stem cells.

Abstract: The invention relates to TGF-&bgr; blocking agent-treated HSC compositions and methods comprising the same. The TGF-&bgr; blocking agent-treated stem cells are viable for an extended time in culture without replication or differentiation and upon transfer to appropriate conditions are capable of long term hematopoietic reconstitution.